Key Takeaways Amgen acquired Dark Blue Therapeutics for about $840M, strengthening its oncology pipeline.AMGN gains a preclinical small-molecule degrader targeting MLLT1/3 proteins tied to certain AML types.Amgen has no marketed AML therapy, but sells Blincyto for ALL and has early AML bispecifics.Amgen (AMGN) announced that it has acquired U.K.-based private biotech company, Dark Blue Therapeutics, for approximately $840 million.The acquisition will strengthen Amgen’s oncology pipeline by adding Dark Blue’ ...

Key Takeaways BMY's growth portfolio rose 17% in the first nine months, while legacy drug sales fell 16% on generics.BMY's Opdivo momentum and Qvantig approval support projected high single- to low double-digit growth.BMY's Reblozyl topped a $2B run rate, Breyanzi passed $1B, while legacy drugs still made up 47% of sales.Bristol Myers Squibb’s (BMY) performance in 2025 reflects an ongoing transition in its revenue base, with growth from newer products partially offsetting continued declines in legacy drugs. ...

- "传统"产品则濒临或已失去专利独占。 两大阵营均有重磅品种坐镇：增长阵营由抗癌药Opdivo领衔，传统阵营则由Eliquis撑盘，尽管后者面临 日益激烈的竞争压力。近期，增量重任主要落在增长类药物肩上——第三季度该板块销售额同比增长 18%，达69亿美元，不仅抵消了传统产品12%的同比下滑，更推动公司总收入增长3%至122亿美元。 智通财经APP获悉，高盛把百时美施贵宝(BMY.US)目标价从 51 美元上调至 57 美元，评级维持"中 性"。该行表示，百时美施贵宝在风险与回报之间展现出一种审慎权衡的平衡：股息率 4.6%，派息率约 85%，即便压力增大，仍留有一定空间支撑股息。 当前，专利悬崖风险已成市场共识。为应对挑战，管理层通过系列收购强化研发管线，并将风险分散至 更多靶点市场——此策略虽非"万能解药"，却在关键节点夯实了企业抗风险能力，通过多元化布局提升 战略纵深，为穿越行业周期提供了更坚实的支撑。 百时美施贵宝专注于心血管、免疫与肿瘤药物的研发与商业化，其产品线被划分为两类： - "增长"药物仍有数年专利护航; 据了解，百时美施贵宝继续定位为一家全球性生物制药公司，致力于发现、开发和交付创新药物 ...

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. Goldman Sachs Raises Bristol-Myers (BMY) Target, Keeps Neutral Rating On December 15, Goldman Sachs raised the firm’s price target on Bristol-Myers Squibb Company (NYSE:BMY) to $57 from $51 and kept a Neutral rating on the shares. Bristol-Myers Squibb Company (NYSE:BMY) presents a measured balance between risk and reward. The stock offers a 4.6% dividend yield, and the payout ratio sits near 85%. ...

Core Insights - Bristol Myers Squibb (BMY) and Amgen (AMGN) are leading global biotechnology companies with diverse portfolios focused on various therapeutic areas [1][2] - Both companies have established strong market positions and consistently delivered shareholder value, making stock selection challenging [3] BMY Overview - BMY's growth portfolio includes drugs such as Opdivo, Reblozyl, and Breyanzi, contributing to strong top-line growth [4][10] - Opdivo sales are driven by its launch in MSI-high colorectal cancer and growth in non-small cell lung cancer, with global sales expected to increase in the high single-digit to low double-digit range by 2025 [5][6] - Reblozyl has annualized sales exceeding $2 billion, significantly boosting BMY's revenue, while Breyanzi sales are also strong, annualizing over $1 billion [7][8] - BMY's legacy portfolio is facing challenges due to generic competition, with expected declines of 15-17% in 2025 [11][12] AMGN Overview - Amgen has a vast portfolio with strong positions in oncology, cardiovascular disease, and rare diseases, supported by growth products like Repatha and Tezspire [13][14] - Despite competitive pressures affecting some products, Amgen's growth trajectory is driven by key drugs and a robust pipeline [15] - The acquisition of Horizon Therapeutics has expanded Amgen's rare disease offerings, enhancing its market position [16] Financial Estimates - BMY's 2025 sales are estimated to decrease by 0.8%, while EPS is expected to increase by 466.09% [17] - AMGN's 2025 sales are projected to grow by 8.78%, with EPS improving by 7.26% [20] Price Performance and Valuation - Over the past six months, BMY has outperformed AMGN slightly, with gains of 13.9% compared to AMGN's 13.5% [21] - In terms of valuation, AMGN trades at a higher forward P/E of 15.2X compared to BMY's 8.99X, indicating a more expensive valuation [21] - BMY offers a higher dividend yield of 4.54% compared to AMGN's 2.86% [22] Investment Considerations - Both companies are considered safe investments in the biotech sector, but AMGN is currently viewed as a better pick due to solid fundamentals and positive estimate revisions [23][25]

Key Points Bristol Myers Squibb's financial results haven't been great in recent years. The giant drugmaker has been facing challenges, including several patent cliffs. New launches, pipeline progress, and a dividend program still make it attractive. 10 stocks we like better than Bristol Myers Squibb › The past five years have been challenging for Bristol Myers Squibb (NYSE: BMY). The company lost patent exclusivity for some key products, including one that was once its best-selling medicine, can ...

Key Points Bristol Myers Squibb is a pharmaceutical giant with a solid dividend history. Medtronic is a high-yield medical device maker that's nearing Dividend King status. J&J makes drugs and medical devices and boasts of over 50 annual dividend increases. 10 stocks we like better than Bristol Myers Squibb › Most dividend investors are looking not just for a high yield, but also for a company that can reliably support that yield over the long term. It is harder to find than you may think, but n ...

Core Insights - Johnson & Johnson (J&J) has a strong R&D pipeline focused on immunology, oncology, and neuroscience, with significant advancements in 2025 [1][2][8] Pipeline and Product Approvals - J&J has achieved major clinical and regulatory milestones, including approvals for Inlexzoh/TAR-200 for high-risk non-muscle invasive bladder cancer and Imaavy (nipocalimab) for generalized myasthenia gravis [2][11] - Nipocalimab is being evaluated for various immune-mediated conditions and is considered to have pipeline-in-a-product potential [3] - Regulatory applications for icotrokinra, an oral treatment for moderate-to-severe plaque psoriasis, have been filed in the US and EU [4] - J&J's new cancer drugs, including Carvykti, Tecvayli, and Talvey, generated $2.14 billion in sales in the first nine months of 2025 [5][11] Strategic Acquisitions and Expansions - The acquisition of Intra-Cellular Therapies added Caplyta, an antidepressant, to J&J's neuroscience portfolio [6] - J&J aims to expand the indications of currently marketed products, with recent approvals for Tremfya, Rybrevant, and Caplyta [7] Long-term Growth Potential - J&J's pipeline execution and recent product approvals position the company for sustained growth beyond short-term pressures, with multiple late-stage assets and significant sales potential across its Innovative Medicine portfolio [8] Competitive Landscape - J&J faces competition in the oncology space from major players like Pfizer, AstraZeneca, Merck, and Bristol-Myers, each with strong oncology portfolios and growth in sales [9][10][12][13][14] Financial Performance and Valuation - J&J's shares have outperformed the industry, rising 42.8% over the past year compared to a 17.5% increase for the industry [15] - The company's shares trade at a price/earnings ratio of 18.09, slightly above the industry average of 17.59 and its five-year mean of 15.65 [18] - The Zacks Consensus Estimate for 2025 earnings has increased from $10.86 to $10.87 per share, indicating positive earnings revisions [20]

Core Insights - Pfizer anticipates a significant revenue decline due to the loss of exclusivity for key products between 2026 and 2030, including Eliquis, Vyndaqel, Ibrance, Xeljanz, and Xtandi, all facing patent expirations [1][9] - The company has bolstered its R&D pipeline through mergers and acquisitions, successful data readouts, and pivotal program initiations, positioning itself for sustainable growth post-LOE [1][7] Oncology Pipeline - Pfizer has advanced its oncology pipeline with several candidates in late-stage development, including vepdegestrant for ER+/HER2- metastatic breast cancer, atirmociclib for HR+/HER2- metastatic breast cancer, and sigvotatug vedotin for metastatic non-small cell lung cancer [2] - By 2030, Pfizer expects to have eight or more blockbuster oncology medicines in its portfolio [4] Non-Oncology Developments - In non-oncology areas, Pfizer is developing an mRNA flu/COVID combination vaccine and osivelotor for sickle cell disease, both in late-stage development [4] - The company is also expanding the labels of approved products like Padcev, which was recently approved by the FDA in combination with Merck's Keytruda for specific bladder cancer patients [5] Obesity Market Expansion - Pfizer is strengthening its presence in the obesity market, currently dominated by Eli Lilly and Novo Nordisk, through the $10 billion acquisition of Metsera and the in-licensing of YP05002, an oral GLP-1 receptor agonist [6] - The Metsera acquisition added four novel clinical-stage programs for obesity, expected to generate billions in peak sales [6] Competitive Landscape - Pfizer faces revenue headwinds from patent expirations but is positioned for long-term growth through its expanding late-stage pipeline in oncology and investments in obesity, vaccines, and rare diseases [7] - The oncology market is competitive, with major players like AstraZeneca, Merck, Johnson & Johnson, and Bristol-Myers also focusing on oncology sales [10][11][12][13] Financial Performance - Pfizer's stock has declined 7% over the past year, while the industry has seen a 16% increase [14] - The company's shares are trading at a forward price/earnings ratio of 8.18, below the industry average of 17.40 and its own 5-year mean of 10.39, indicating attractive valuation [16] - The Zacks Consensus Estimate for 2025 earnings has increased slightly to $3.10 per share, while the estimate for 2026 has decreased to $3.04 per share [18]

Key Takeaways BMY will give Eliquis free to Medicaid and donate more than 7 tons of its active ingredient. Eliquis is Bristol Myers Squibb's top drug, posting $11B in sales in the first nine months of 2025. The government deal grants BMY three years of tariff relief and no future pricing mandates.Bristol Myers Squibb (BMY) announced a pricing agreement with the U.S. government to supply Eliquis (apixaban) at no cost to Medicaid beginning Jan. 1, 2026. BMY will also donate more than 7 tons of the active phar ...